Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GW274150 phosphate is a selective, orally active, and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50: 2.19 μM; Kd: 40 nM) and rat iNOS (ED50: 1.15 μM).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 447 | 5日内发货 | ||
5 mg | ¥ 747 | 5日内发货 | ||
10 mg | ¥ 1,460 | 5日内发货 | ||
100 mg | ¥ 6,650 | 8-10周 |
GW274150 phosphate 的其他形式现货产品:
产品描述 | GW274150 phosphate is a selective, orally active, and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50: 2.19 μM; Kd: 40 nM) and rat iNOS (ED50: 1.15 μM). |
靶点活性 | eNOS (human):544 μM (Kd) |
体外活性 | GW274150 is >260-fold and 219-fold selective for iNOS against eNOS and nNOS in rat tissues, respectively. And it displays >100-fold and >80-fold for human iNOS against human eNOS and nNOS, respectively.GW274150 phosphate inhibits intracellular iNOS in J774 cells in a time-dependent manner, reaching IC50 values of 0.2±0.04 μM. |
体内活性 | GW274150 phosphate (oral adminstration; 30 mg/kg; twice daily; 7 days) leads to significant neuroprotection, however, it displays a bell-shaped neuroprotective profile, being ineffective at high doses in 6-OHDA rat model of Parkinson disease (PD).GW274150 phosphate is a long-acting (5 h half‐life in rats) iNOS inhibitor and is able to inhibit LPS‐mediated increase in plasma NO2-, NO3- levels 14 h after single intraperitoneal dose (ED50=3 mg/kg).GW274150 phosphate (intraperitoneal injection;?2.5, 5, and 10 mg/kg;?before carrageenan injection) reduces the degree of lung injury induced by carrageenan in a dose-related fashion.?Oedema formation and PMNs infiltration in the pleural cavity are also significantly attenuated in a dose‐related manner in rats. |
分子量 | 317.3 |
分子式 | C8H20N3O6PS |
CAS No. | 438542-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 100 mg/mL (315.16 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 3.1516 mL | 15.758 mL | 31.5159 mL | 78.7898 mL |
5 mM | 0.6303 mL | 3.1516 mL | 6.3032 mL | 15.758 mL | |
10 mM | 0.3152 mL | 1.5758 mL | 3.1516 mL | 7.879 mL | |
20 mM | 0.1576 mL | 0.7879 mL | 1.5758 mL | 3.9395 mL | |
50 mM | 0.063 mL | 0.3152 mL | 0.6303 mL | 1.5758 mL | |
100 mM | 0.0315 mL | 0.1576 mL | 0.3152 mL | 0.7879 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GW274150 phosphate 438542-15-5 Immunology/Inflammation NOS GW274150 Phosphate GW-274150 Phosphate GW-274150 phosphate GW 274150 Phosphate Inhibitor inhibitor inhibit